A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
|Slideshows|November 7, 2014
The Surgeon General vs the Marlboro Man: Who Really Won?
Author(s)Alan Blum, MD
The images in this slide set are from an exhibition curated by Alan Blum, MD, at the University of Alabama Gorgas Library (November to December 2013) to commemorate the 50th anniversary of the Surgeon General’s Report on Smoking and Health, released on January 11, 1964 by Dr. Luther Terry.
Advertisement
Advertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
3
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
4
Distinguishing HER2 Mutations From Amplification in NSCLC Testing
5